367 related articles for article (PubMed ID: 27272266)
21. A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients.
Bosheva M; Gujabidze R; Károly É; Nemeth A; Saulay M; Smart JI; Hamed KA
Pediatr Infect Dis J; 2021 Jun; 40(6):e222-e229. PubMed ID: 33480665
[TBL] [Abstract][Full Text] [Related]
22. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis.
Riccobene T; Jakate A; Rank D
J Clin Pharmacol; 2014 Jul; 54(7):742-52. PubMed ID: 24431097
[TBL] [Abstract][Full Text] [Related]
23. Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia.
Zheng Y; Liu SP; Xu BP; Shi ZR; Wang K; Yang JB; Huang X; Tang BH; Chen XK; Shi HY; Zhou Y; Wu YE; Qi H; Jacqz-Aigrain E; Shen AD; Zhao W
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941652
[TBL] [Abstract][Full Text] [Related]
24. Ceftobiprole and pneumonia in adults admitted to the emergency department is it time to assess a new therapeutic algorithm?
Crapis M; Venturini S; Della Siega P; Tonizzo M; Garlatti E; Rosa R; Basso B; Pontoni E
J Chemother; 2021 May; 33(3):174-179. PubMed ID: 32996844
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose intravenous ceftobiprole in healthy Chinese participants.
Li WZ; Wu HL; Chen YC; Guo BN; Liu XF; Wang Y; Wu JF; Zhang J
Ann Transl Med; 2021 Jun; 9(11):936. PubMed ID: 34350251
[TBL] [Abstract][Full Text] [Related]
26. Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study.
Muller AE; Schmitt-Hoffmann AH; Punt N; Mouton JW
Antimicrob Agents Chemother; 2013 May; 57(5):2047-53. PubMed ID: 23403430
[TBL] [Abstract][Full Text] [Related]
27. Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Dauner DG; Nelson RE; Taketa DC
Am J Health Syst Pharm; 2010 Jun; 67(12):983-93. PubMed ID: 20516468
[TBL] [Abstract][Full Text] [Related]
28. Ceftobiprole medocaril for the treatment of pneumonia.
Hsu WH; Hsu CK; Lai CC
Expert Rev Anti Infect Ther; 2023 Jun; 21(6):551-563. PubMed ID: 37042813
[TBL] [Abstract][Full Text] [Related]
29. Ceftobiprole medocaril.
Méndez R; Latorre A; González-Jiménez P
Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):25-27. PubMed ID: 35488820
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Canut A; Isla A; Rodríguez-Gascón A
Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
[TBL] [Abstract][Full Text] [Related]
31. Ceftobiprole: a new broad spectrum cephalosporin.
El Solh A
Expert Opin Pharmacother; 2009 Jul; 10(10):1675-86. PubMed ID: 19527192
[TBL] [Abstract][Full Text] [Related]
32. Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients.
Rubino CM; Cammarata AP; Smits A; Schröpf S; Polak M; Litherland K; Hamed K
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0120621. PubMed ID: 34398669
[TBL] [Abstract][Full Text] [Related]
33. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
Anderson SD; Gums JG
Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic/Pharmacodynamics-Optimized Antimicrobial Therapy in Patients with Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia.
Sulaiman H; Abdul-Aziz MH; Roberts JA
Semin Respir Crit Care Med; 2017 Jun; 38(3):271-286. PubMed ID: 28578552
[TBL] [Abstract][Full Text] [Related]
35. Ceftaroline Dosage Optimized for Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling.
Zhou J; You X; Guo G; Ke M; Xu J; Ye L; Wu W; Huang P; Lin C
J Clin Pharmacol; 2021 Dec; 61(12):1646-1656. PubMed ID: 34329494
[TBL] [Abstract][Full Text] [Related]
36. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.
Rodvold KA; Nicolau DP; Lodise TP; Khashab M; Noel GJ; Kahn JB; Gotfried M; Murray SA; Nicholson S; Laohavaleeson S; Tessier PR; Drusano GL
Antimicrob Agents Chemother; 2009 Aug; 53(8):3294-301. PubMed ID: 19451287
[TBL] [Abstract][Full Text] [Related]
37. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Barbour A; Schmidt S; Rand KH; Derendorf H
Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
[TBL] [Abstract][Full Text] [Related]
38. Is continuous infusion of imipenem always the best choice?
Suchánková H; Lipš M; Urbánek K; Neely MN; Strojil J
Int J Antimicrob Agents; 2017 Mar; 49(3):348-354. PubMed ID: 28189734
[TBL] [Abstract][Full Text] [Related]
39. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.
Nicholson SC; Welte T; File TM; Strauss RS; Michiels B; Kaul P; Balis D; Arbit D; Amsler K; Noel GJ
Int J Antimicrob Agents; 2012 Mar; 39(3):240-6. PubMed ID: 22230331
[TBL] [Abstract][Full Text] [Related]
40. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
Noel GJ
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():25-9. PubMed ID: 17488373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
